0001279569-24-001454.txt : 20241206 0001279569-24-001454.hdr.sgml : 20241206 20241206070039 ACCESSION NUMBER: 0001279569-24-001454 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240605 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20241206 DATE AS OF CHANGE: 20241206 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ESSA Pharma Inc. CENTRAL INDEX KEY: 0001633932 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37410 FILM NUMBER: 241530521 BUSINESS ADDRESS: STREET 1: SUITE 720 STREET 2: 999 WEST BROADWAY CITY: VANCOUVER STATE: A1 ZIP: V5Z 1K5 BUSINESS PHONE: (778) 331-0962 MAIL ADDRESS: STREET 1: SUITE 720 STREET 2: 999 WEST BROADWAY CITY: VANCOUVER STATE: A1 ZIP: V5Z 1K5 8-K 1 form8k.htm FORM 8-K
false 0001633932 A1 0001633932 2024-06-05 2024-06-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): June 5, 2024

ESSA Pharma Inc.

(Exact name of registrant as specified in its charter)

 

 

British Columbia, Canada

(State or other jurisdiction of incorporation)

001-37410

(Commission File Number)

98-1250703

(IRS Employer Identification No.)

 

Suite 720, 999 West Broadway, Vancouver, British Columbia, Canada
(Address of principal executive offices)
V5Z 1K5
(Zip Code)

 

Registrant’s telephone number, including area code: (778) 331-0962

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Shares, no par value EPIX Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 
 

 

Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 5, 2024, after a lengthy and thorough review process, the Board of Directors of ESSA Pharma Inc. (the “Company”) adopted and approved the ESSA Pharma Inc. Severance Plan (the “Severance Plan”), which, for certain terminations of employment, replaces the cash severance benefits previously provided under the employment agreements of certain executive officers. The Company’s named executive officers and certain other executives will participate in the Severance Plan. Capitalized terms used but not defined herein have the definitions ascribed to such terms in the Severance Plan.

In the event of a Qualifying Termination, the Severance Plan provides for (i) cash severance ranging from 1 to 1.5 times of such officer’s base salary (and in the case of the Chief Executive Officer, their target bonus in addition to base salary), with the larger multiple payable on a Qualifying Termination in connection with a Change in Control of the Company and (ii) certain benefits continuation following termination. Severance payments and benefits under the Severance Plan are subject to the executive’s execution of a release of claims in favor of the Company. 

The foregoing description of the Severance Plan is qualified in its entirety by reference to the full text of the Severance Plan, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.


(d) Exhibits

Exhibit No.

Description

 
99.1 ESSA Pharma Inc. Executive Severance Plan

 

 
 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    ESSA PHARMA INC.____________
    (Registrant)
Date: December 6, 2024    
  By:  /s/ David Wood
    Name: David Wood
    Title: Chief Financial Officer

 

EX-99.1 2 ex991.htm SEVERANCE PLAN

Exhibit 99.1

ESSA PHARMA INC.

SEVERANCE PLAN

 

Section 1. Purpose of the Plan

This ESSA Pharma Inc. Severance Plan (the “Plan”) is intended to promote the interests of the Company by helping the Company retain qualified executives, maintain a stable work environment and provide economic security to eligible executives in the event of certain qualifying terminations of employment, including in connection with a Change in Control of the Company, and subject to the terms of the Plan. It is also contemplated that the Plan will enhance the ability of the Company and its wholly-owned Subsidiaries to attract and retain the services of individuals who are essential for the growth and profitability of the Company and to encourage them to devote their best efforts to the business of the Company, thereby advancing the interests of the Company. Capitalized terms used but not otherwise defined herein have the meanings set forth in Section 2.

The Plan is not intended to be included in the definitions of “employee pension benefit plan” or “pension plan” set forth under Section 3(2) of ERISA. The Plan is intended to meet the descriptive requirements of a plan constituting a “severance pay plan” within the meaning of regulations published by the Secretary of Labor at Title 29, Code of Federal Regulations, Section 2510.3-2(b). Notwithstanding the foregoing, if and to the extent that the Plan is deemed to be an “employee pension benefit plan” or “pension plan” as set forth under Section 3(2) of ERISA, then the Plan is intended, for all purposes under ERISA, to constitute a plan that is unfunded and maintained by the Company primarily for the purposes of providing deferred compensation for a select group of management or highly compensated employees.

 

Section 2. Definitions

As used in the Plan, the following terms shall have the meanings set forth below:

(a)       “Affiliate” shall have the meaning set forth in the Omnibus Plan.

(b)       “Base Salary” means a Participant’s annual base salary as in effect immediately prior to the Qualifying Termination Date or, if higher, as in effect immediately prior to the occurrence of an event or circumstance constituting Good Reason.

(c)       “Benefit Subsidy” means, to the extent a Participant employed in the United States shall have elected continuation coverage under the Consolidated Budget Reconciliation Act of 1985, as amended, the Company’s provision of continued participation to the Participant and his or her eligible dependents in the health, dental and vision benefit plans of the Company in which the Participant participated immediately prior to the Participant’s Qualifying Termination (or, if more favorable, immediately before any circumstance giving rise to Good Reason) on the same basis as similarly situated active employees from time to time or, if continued participation in such plans is not possible, substantially equivalent coverage or, to the extent such Benefit Subsidy would result in a taxable event to the Participant, the Company’s payment to the Participant of an amount equal to the lesser of (i) the amount that the Company determines is sufficient to obtain substantially comparable insurance coverage, and (ii) the amount the Company would have contributed (or been deemed to contribute) to coverage had continued participation in the applicable Company plan had such participation been possible. If a Participant is not enrolled in a group health plan sponsored by the Company or an Affiliate as of the immediately prior to the Qualifying Termination Date, the term Benefit Subsidy shall mean for such Participant a payment equal to the amount that the Company determines the Company would have contributed to such coverage had the Participant participated in such a plan during the Continuation Period.

 
 

 

 

(d)       “Board” means the board of directors of the Company.

(e)       “C-Level” Executive means the Company’s Chief Financial Officer, Chief Operating Officer and Chief Medical Officer.

(f)       “Cause” shall have the meaning set forth in the Omnibus Plan.

(g)       “Change in Control” shall have the meaning set forth in the Omnibus Plan.

(h)       “Code” shall have the meaning set forth in the Omnibus Plan.

(i)       “Company” means ESSA Pharma Inc., a company incorporated under the laws of the Province of British Columbia, and, except as the context otherwise requires, its wholly-owned Subsidiaries and any successor by merger, acquisition, consolidation or otherwise that assumes the obligations of the Company under the Plan.

(j)       “Continuation Period” means:

(i)       with respect to a Participant who is a Vice President, the period beginning on his or her Qualifying Termination Date and ending three (3) months following such date (or six (6) months in the event of a Qualifying Termination Date during the Covered Period) or (ii) if earlier, the date on which the Participant becomes eligible to receive health, dental and vision coverage on substantially similar terms from another employer;

(ii)       with respect to a Participant who is a Senior Vice President, the period beginning on his or her Qualifying Termination Date and ending six (6) months following such date (or nine (9) months in the event of a Qualifying Termination Date during the Covered Period) or (ii) if earlier, the date on which the Participant becomes eligible to receive health, dental and vision coverage on substantially similar terms from another employer.

(iii)       with respect to a Participant who is a the Chief Executive Officer or a C-Level Executive, the period beginning on his or her Qualifying Termination Date and ending one year following such date (or eighteen months in the event of a Qualifying Termination Date during the Covered Period) or (ii) if earlier, the date on which the Participant becomes eligible to receive health, dental and vision coverage on substantially similar terms from another employer.

(k)       “Covered Period” means the period of time beginning sixty (60) days immediately prior to the first occurrence of either a Change in Control or, if earlier, the execution by the Company of an agreement, the consummation of which would result in a Change in Control, and lasting through the first anniversary of the occurrence of the Change in Control.

(l)       “Disability” shall have the meaning set forth in the Omnibus Plan.

(m)       “ERISA” means the Employee Retirement Income Security Act of 1974, as amended. Any reference to a section of ERISA shall be deemed to include a reference to any regulations promulgated thereunder.

(n)       “Good Reason” means the occurrence of any of the following conditions: (i) a material adverse change in the nature of the Participant’s duties or responsibilities from those in effect at the time the individual becomes a Participant hereunder (as such duties or responsibilities may be increased from time to time); (ii) a material reduction in the Participant’s base compensation or short-term cash incentive compensation opportunities from those in effect at the time the individual becomes a Participant hereunder (as such base compensation or short-term cash incentive compensation opportunities may be increased from time to time); or (iii) a mandatory relocation of Participant’s principal place of work in excess of 50 miles.

 2 

 

 

Notwithstanding the foregoing, a condition shall not constitute “Good Reason” for purposes of the Plan unless (a) within 30 days following the first occurrence of such condition, the Participant delivers written notice to the Company of his or her intent to terminate employment for Good Reason based on such condition, and (b) within 30 days following its receipt of such notice, the Company has not substantially cured such condition. For the avoidance of doubt, the occurrence of a Change in Control (including a Change in Control in which the Company becomes a subsidiary of another entity) shall not itself constitute Good Reason.

(o)       “Omnibus Plan” means the ESSA Pharma Inc. 2022 Omnibus Incentive Plan, as in effect on the Effective Date.

(p)       “Participant” means each officer of the Company or its wholly-owned Subsidiaries who may be designated by the Administrator as a Participant from time to time pursuant to Section 4, as identified on Annex A attached hereto, as amended from time to time (subject to any written agreement between a Participant and the Company). Changes to Annex A shall not be permitted during Covered Period, to the extent such changes would be adverse to a Participant.

(q)       “Person” shall have the meaning set forth in the Omnibus Plan.

(r)       “Plan” means this ESSA Pharma Inc. Severance Plan, as may be amended and/or restated from time to time in accordance with the terms hereof.

(s)       “Qualifying Termination” means the termination of a Participant’s employment either by the Company without Cause (at any time) or during the Covered Period by the Participant for Good Reason.

(t)       “Qualifying Termination Date” means the date on which a Participant incurs a Qualifying Termination.

(u)       The “Severance Multiple” of any Participant shall be as set forth in the matrix below:

 

Position Severance Multiple Severance Multiple for Qualifying Termination Date During Covered Period
Chief Executive Officer and C-Level Executives 1 1.5
Senior Vice President 0.5 0.75
Vice President 0.25 0.5

 

(v)       “Severance Payment” means (A) for any Participant other than the Chief Executive Officer of the Company, a lump-sum cash payment equal to the product of (i) such Participant’s Base Salary and (ii) the applicable Severance Multiple and (B) for the Chief Executive Officer of the Company, a lump-sum cash payment equal to the product of (i) the sum of (x) such Participant’s Base Salary and (y) such Participant’s target annual cash bonus (without giving effect to any action constituting Good Reason) and (ii) the applicable Severance Multiple.

 3 

 

 

 

Section 3. Administration

(a)       General Authority. The Plan shall be administered by the Board or, as and to the extent designated by the Board from time to time, a committee thereof, one or more employees of the Company, or one or more members of the Board together with one or more employees of the Company (collectively, the “Administrator”), subject to such limitations on such delegated powers and duties as the Board may impose.

(b)       Determinations. Subject to the terms of the Plan and applicable law, and in addition to other express powers and authorizations set forth in the Plan, the Administrator shall have full power and authority to: (i) designate Participants; (ii) interpret and administer the Plan; (iii) establish, amend, suspend, or waive such rules and regulations and appoint such agents as it shall deem appropriate for the proper administration of the Plan; and (iv) make any other determination and take any other action that the Administrator deems necessary or desirable for the administration of the Plan. The Administrator shall have full power and express discretionary authority to make factual determinations and to adopt or amend such rules, regulations, agreements, and instruments for implementing the Plan and for the conduct of its business as it deems necessary or advisable, in its sole discretion. Unless otherwise expressly provided in the Plan, all designations, determinations, interpretations, and other decisions under or with respect to the Plan shall be within the sole discretion of the Administrator, may be made at any time and shall be final, conclusive, and binding upon all Persons. Administration of the Plan need not be uniform as to similarly situated Participants.

 

Section 4. Eligibility

Any officer of the Company or its wholly-owned Subsidiaries shall be eligible to be designated a participant in the Plan. With respect to any individual who is identified on Annex A as a Participant who is party to an agreement with the Company or an Affiliate which provides for severance payments or benefits, participation in the Plan shall be conditioned on the execution by such individual of a waiver of the severance entitlements under such agreement, in such form as shall be determined by the Administrator.

 

Section 5. Qualifying Termination

(a)       Amount. In the event a Participant incurs a Qualifying Termination, provided that the Participant executes and does not revoke a customary release of claims in a form and manner reasonably satisfactory to the Company (the “Release”) within sixty (60) days following the Qualifying Termination Date, the Company shall provide (or cause to be provided) to the Participant: (i) the Severance Payment, and (ii) the Benefit Subsidy during the applicable Continuation Period, paid or provided as soon as practicable (but in any event within five (5) days) after the Release becomes irrevocable, subject to Section 9(a) and Section 9(e). In the event that a Participant experiences a Qualifying Termination and such Qualifying Termination is later determined to have occurred during the Covered Period, the Company shall immediately pay to the Participant the additional amounts which would have been payable to the Participant had such Qualifying Termination been initially determined to have occurred during the Covered Period.

(b)       No Transfer. No right under the Plan may be assigned, alienated, pledged, attached, sold, or otherwise transferred or encumbered by a Participant and any such purported assignment, alienation, pledge, attachment, sale, transfer, or encumbrance shall be void and unenforceable against the Company or any Affiliate.

 

Section 6. Term and Termination

(a)       The Plan shall be effective as of June 5, 2024, the date the Plan was approved by the Board (the “Effective Date”), and shall continue in effect indefinitely; provided that the Plan may be amended or terminated subject to subsection 6(b) below.

 4 

 

 

(b)       Except to the extent prohibited by applicable law or specifically set forth in a written agreement between a Participant and the Company, the Board may amend, alter, suspend, discontinue, or terminate the Plan, provided that during a Covered Period, no such amendment, alteration, suspension, discontinuance or termination shall impair the rights of a Participant under the Plan.

 

Section 7. Effect on Other Plans, Agreements and Benefits

(a)       It shall be a condition to an individual’s eligibility to be a Participant that such individual agree that that the Plan constitutes the sole source of any severance, termination or similar benefits and, to the extent applicable, supersedes and other contractual or other severance or similar entitlements. Each Participant who incurs a Qualifying Termination shall remain entitled to any benefits to which he or she would otherwise be entitled under the terms and conditions of the Company’s other compensation and benefit plans, programs and arrangements (other than any severance or termination benefit plans, programs, policies or agreements), and nothing contained in the Plan is intended to waive or relinquish the Participant’s rights thereunder.

(b)       Any severance benefits payable to a Participant under the Plan shall not be counted as compensation for purposes of determining benefits under any other benefit policies or plans of the Company or its wholly-owned Subsidiaries, except to the extent expressly provided therein.

(c)       Notwithstanding anything set forth herein to the contrary, to the extent that any severance payable under a plan or agreement covering a Participant as of the date such Participant becomes eligible to participate in this Plan constitutes deferred compensation under Section 409A of the Code, then to the extent required to avoid accelerated taxation and/or tax penalties under Section 409A of the Code, the portion of the benefits payable hereunder equal to such other amount shall instead be provided in the form set forth in such other plan or agreement.

 

Section 8. Section 280G

(a)       Treatment of Payments. Notwithstanding any other provision of the Plan to the contrary, in the event that any payment or benefit received or to be received by a Participant (whether pursuant to the terms of the Plan or any other plan, arrangement or agreement) (all such payments and benefits, including the severance benefits payable hereunder, being hereinafter referred to as the “Total Payments”) would be subject (in whole or part) to any excise tax imposed on the Participant under Section 4999 of the Code (the “Excise Tax”), then, after taking into account any reduction in the Total Payments provided by reason of Section 280G of the Code in such other plan, arrangement or agreement, the severance benefits payable hereunder shall be reduced to the extent necessary so that no portion of the Total Payments is subject to the Excise Tax but only if the net amount of such Total Payments, as so reduced (and after subtracting the net amount of federal, state and local income taxes on such reduced Total Payments and after taking into account the phase out of itemized deductions and personal exemptions attributable to such reduced Total Payments) is greater than or equal to the net amount of such Total Payments without such reduction (but after subtracting the net amount of federal, state and local income taxes on such Total Payments and the amount of Excise Tax to which the Participant would be subject in respect of such unreduced Total Payments and after taking into account the phase out of itemized deductions and personal exemptions attributable to such unreduced Total Payments).

 5 

 

 

(b)       Ordering of Reduction. In the case of a reduction in the Total Payments pursuant to Section 8(a), the Total Payments shall be reduced in the following order: (i) payments that are payable in cash the full amount of which are treated as parachute payments under Treasury Regulation Section 1.280G-1, Q&A 24(a) shall be reduced (if necessary, to zero), with amounts that are payable last reduced first; (ii) payments and benefits due in respect of any equity the full amount of which are treated as parachute payments under Treasury Regulation Section 1.280G-1, Q&A 24(a), with the highest values reduced first (as such values are determined under Treasury Regulation Section 1.280G-1, Q&A 24), shall next be reduced; (iii) payments that are payable in cash that are valued at less than full value under Treasury Regulation Section 1.280G-1, Q&A 24, with amounts that are payable last reduced first, shall next be reduced; (iv) payments and benefits due in respect of any equity valued at less than full value under Treasury Regulation Section 1.280G-1, Q&A 24, with the highest values reduced first (as such values are determined under Treasury Regulation Section 1.280G-1, Q&A 24), shall next be reduced; and (v) all other non-cash benefits not otherwise described in clauses (ii) or (iv) shall be next reduced pro-rata.

(c)       Additional Payments. If a Participant receives reduced payments and benefits by reason of this Section 8 and it is established pursuant to a determination of a court of competent jurisdiction, which determination is not subject to review or as to which the time to appeal such determination has expired, or pursuant to an Internal Revenue Service proceeding, that the Participant could have received a greater amount without resulting in any Excise Tax, then the Company shall thereafter pay the Participant the aggregate additional amount which could have been paid without resulting in any Excise Tax as soon as reasonably practicable.

 

Section 9. General Provisions

(a)       Withholding. All payments and benefits hereunder shall be subject to applicable federal (including FICA), state, and local tax withholding requirements. The Company may deduct from any payment made under the Plan the amount of any withholding taxes due with respect thereto, as determined by the Administrator in its sole discretion.

(b)       No Right to Employment. Participation in the Plan shall not be construed as giving a Participant the right to be retained in the employ or service of the Company or any Affiliate.

(c)       Governing Law. The validity, construction, and effect of the Plan and any rules and regulations relating to the Plan shall be determined in accordance with the laws of the State of Texas (without regard to any choice of law provision that might refer interpretation of the Plan to the substantive law of another jurisdiction) and applicable Canadian and United States federal law. Notwithstanding anything in the Plan to the contrary, the provisions of the Plan shall be altered for participants who are employed by the Company or an Affiliate in Canada in the manner set forth in Appendix A.

(d)       Severability. If any provision of the Plan is or becomes or is deemed to be invalid, illegal, or unenforceable in any jurisdiction or as to any Participant, such provision shall be construed or deemed amended to conform to the applicable laws, or if it cannot be construed or deemed amended without, in the determination of the Administrator, materially altering the intent of the Plan, such provision shall be stricken as to such jurisdiction or Participant and the remainder of the Plan shall remain in full force and effect.

(e)       Compliance with Other Laws. It is intended that, to the extent applicable, payments and benefits under the Plan be exempt from or, if not so exempt, comply with, the requirements of Section 409A of the Code and the regulations thereunder to the extent required to avoid accelerated taxation and/or tax penalties under Section 409A of the Code, and the Plan shall be interpreted consistently with this intent. Notwithstanding anything in the Plan to the contrary, any benefit under the Plan that is considered nonqualified deferred compensation under Section 409A of the Code shall be payable only upon a Participant’s “separation from service” with the Company and its Affiliates within the meaning of Section 409A of the Code. If a Participant is a “specified employee” (as defined in Section 409A of the Code), then to the extent required to avoid accelerated taxation and/or tax penalties under Section 409A of the Code, such Participant shall not be entitled to any payments upon a termination of his or her employment or service until the earlier of: (i) the expiration of the six (6)-month period measured from the date of such Participant’s “separation from service” or (ii) the date of such Participant’s death.

 6 

 

 

Notwithstanding anything in the Plan to the contrary, in the event any payments hereunder could occur in one of two calendar years as a result of being dependent upon the Release becoming irrevocable, then, to the extent required to avoid the imposition of taxes and penalties under Section 409A of the Code, such payments shall commence on the first regularly scheduled payroll date of the Company, following the date the Release becomes irrevocable, that occurs in the second of such two calendar years.

(f)       No Trust or Fund Created. Neither the Plan nor any right to a payment or benefit under the Plan shall create or be construed to create a trust or separate fund of any kind or a fiduciary relationship between the Company or any Affiliate and a Participant.

(g)       Headings. Headings are given to the sections and subsections of the Plan solely as a convenience to facilitate reference. Such headings shall not be deemed in any way material or relevant to the construction or interpretation of the Plan or any provision thereof.

(h)       Applicable Policies. All payments and benefits under the Plan shall be subject to the terms of the Company’s clawback policy, as may be amended and/or restated from time to time and pursuant to the terms thereunder.

 7 

 

ANNEX A

PARTICIPANT LIST

 

David Parkinson, President and Chief Executive Officer

Peter Virsik, Executive Vice President and Chief Operating Officer

Alessandra Cesano, Executive Vice President and Chief Medical Officer

David Wood, Chief Financial Officer

Han-Jie Zhou, Senior Vice President

Karen Villaluna, Vice President

 8 

 

 

APPENDIX A

 

[Variation of Plan terms for Canadian Participants, if any]

 9 
EX-101.LAB 3 epix-20240605_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 4 epix-20240605_pre.xml XBRL PRESENTATION FILE EX-101.SCH 5 epix-20240605.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.3
Cover
Jun. 05, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 05, 2024
Entity File Number 001-37410
Entity Registrant Name ESSA Pharma Inc.
Entity Central Index Key 0001633932
Entity Tax Identification Number 98-1250703
Entity Incorporation, State or Country Code A1
Entity Address, Address Line One Suite 720
Entity Address, Address Line Two 999 West Broadway
Entity Address, City or Town Vancouver
Entity Address, State or Province BC
Entity Address, Country CA
Entity Address, Postal Zip Code V5Z 1K5
City Area Code 778
Local Phone Number 331-0962
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Shares, no par value
Trading Symbol EPIX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://essapharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports epix-20240605.xsd epix-20240605_lab.xml epix-20240605_pre.xml form8k.htm http://xbrl.sec.gov/dei/2024 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8k.htm": { "nsprefix": "EPIX", "nsuri": "http://essapharma.com/20240605", "dts": { "schema": { "local": [ "epix-20240605.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "labelLink": { "local": [ "epix-20240605_lab.xml" ] }, "presentationLink": { "local": [ "epix-20240605_pre.xml" ] }, "inline": { "local": [ "form8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2024": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 24 }, "report": { "R1": { "role": "http://essapharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-06-05", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-05", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://essapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001279569-24-001454-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001279569-24-001454-xbrl.zip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form8k_htm.xml IDEA: XBRL DOCUMENT 0001633932 2024-06-05 2024-06-05 iso4217:USD shares iso4217:USD shares false 0001633932 A1 8-K 2024-06-05 ESSA Pharma Inc. 001-37410 98-1250703 Suite 720 999 West Broadway Vancouver BC CA V5Z 1K5 778 331-0962 false false false false Common Shares, no par value EPIX NASDAQ false